Latest Articles
-
Boston Scientific Earnings Preview: New Products and Margins In Focus
Boston Scientific (NYSE:BSX) is scheduled to release its earnings for Q3 2013 on October 24. The medical device maker’s revenue has been declining since 2009 due to increased competition and pricing pressures. However, it has been rebuilding its ...
-
4 Biggest Stocks With The Latest Dividend Growth To Observe
Submitted by Dividend Yield as part of our contributors program . 4 Biggest Stocks With The Latest Dividend Growth To Observe Stocks with dividend hikes from last week originally published at long-term-investments.blogspot.com . 30 companies...
-
Abbott Continues Growth On Diagnostics Sales And Margin Improvement
Abbott ’s (NYSE:ABT) Q3 results are a good example of the benefits of diversification. Nutritionals, the company’s largest segment, is currently ailing from a sales disruption in some key emerging markets. However, the company reported a 4.3% yea...
-
Abbott Earnings Preview: Nutritionals And Diagnostics Divisions In Focus
Abbott Labs (NYSE:ABT) is scheduled to release its results for Q3 on October 16. In the previous quarter, the company’s net revenue grew by 4.2% year-over-year on an operational basis as the Nutritionals and Diagnostics registered operational sal...
-
Biotech Merger And Acquisition Rumors And News
Submitted by Scott Matusow as part of our contributors program . Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. However, there is no way to know for sure since I am not an insider and have n...
-
A Look At Abbott’s Branded Generic Drug Business
At the beginning of this year, Abbott Laboratories (NYSE:ABT) spun of its proprietary pharmaceutical business as Abbvie Inc. (NYSE:ABBV). It however retained its portfolio of branded generic medicines (also called “established” medicines). This p...
-
Ken Fisher’s Biggest Dividend Stock Buys And His Latest Portfolio
Submitted by Dividend Yield as part of our contributors program . Ken Fisher’s stock purchases and his portfolio overview originally published at long-term-investments.blogspot.com . I often look at the activities of the big players be...
-
AcelRx May Be In Play For Acquisition Soon: NDA To Be Filed At Month’s End
Submitted by Scott Matusow as part of our contributors program . We believe that AcelRx Pharmaceuticals (NASDAQ: ACRX) warrants a close look by both longer-term investors and shorter-term catalyst traders. We have been hearing some strong...
-
A Dozen Low-Priced Dividend Aristocrats That Analysts Love To Recommend
Submitted by Dividend Yield as part of our contributors program . A Dozen Low-Priced Dividend Aristocrats That Analysts Love To Recommend Dividend Aristocrats with low P/E’s and buying recommendations originally published at long-term-...
-
Hedge Fund Manager George Soros And His Latest Best Yielding Stock Purchases
Submitted by Dividend Yield as part of our contributors program . Georges Soros latest dividend stock moves and his asset allocation originally published at long-term-investments.blogspot.com . George Soros is a legendary and speculative drive...
-
Why Abbott’s Troubles With Chinese Regulators Are Not A Big Deal
Abbott Labs’ (NYSE:ABT) Chinese baby formula business faced two small setbacks last week. First, the company was fined around 77 million Yuan ($12.63 million) for allegedly collaborating with several competitors to fix the prices of its baby form...
-
Voce Capital Pushes For Acquisition Of Solta Medical, Activist Investor David Callan Joins In
Submitted by Scott Matusow as part of our contributors program . Merger and acquisition speculation is one of the most interesting and exciting elements of the stock market. Sometimes both activist institutions and private investors can levera...
-
10 Cheap Income Growth Stocks From The S&P High-Yield Dividend Aristocrats Index
Submitted by Dividend Yield as part of our contributors program . Stocks from the S&P High Yield Dividend Aristocrats with strong growth at low valuation originally published at long-term-investments.blogspot.com . Is there anybody who don...
-
Nutritionals And Diagnostics Continue To Drive Abbott’s Growth
Abbott Labs (NYSE:ABT) reported its earnings for Q2 2013 on July 17. It was another good quarter for the company as the Nutritionals and Diagnostics divisions, which together account for nearly half of the value in the company according to our es...
-
Abbott Earnings Preview: Emerging Markets And Profit Margin In Focus
Abbott Laboratories (NYSE:ABT) is scheduled to release its earnings for Q2 2013 on July 17th. In the previous quarter, the company reported that its total revenue was almost $5.4 billion, up 3.5% from the same period last year on an operational b...
